PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …

The optimal management approach to advanced or metastatic renal cell cancer of the clear
cell type continues to rapidly evolve. Risk stratification of patients into favorable …

Background The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC)
has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more …

The therapeutic landscape for advanced clear cell renal cell carcinoma (ccRCC) is rapidly
evolving with improved knowledge of the biology of disease leading to the incorporation of a …

BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF)
pathway is a standard of care for patients with metastatic renal cell carcinoma (RCC). The …

Abstract Background Immune checkpoint inhibitors (ICIs) are being increasingly utilised in
the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC). Limited …

Context Systemic therapy for metastatic clear cell renal cell carcinoma (mccRCC) has
greatly evolved over the last 15 yr. More recently, combination strategies involving …

The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the
combination of ipilimumab and nivolumab when compared with the previous standard of …

Purpose: We developed a clinically useful scoring algorithm to predict cancer specific
survival for patients with clear cell metastatic renal cell carcinoma (RCC). Materials and …